The AERI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AERI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The AERI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View AERI Detailed Price Forecast - CNN Money||View AERI Detailed Summary - Google Finance|
|View AERI Detailed Summary - Yahoo! Finance||View AERI Stock Research & Analysis - Zacks.com|
|View AERI Trends & Analysis - Trade-Ideas||View AERI Major Holders - Barrons|
|View AERI Call Transcripts - NASDAQ||View AERI Breaking News & Analysis - Seeking Alpha|
|View AERI Annual Report - CompanySpotlight.com||View AERI OTC Short Report - OTCShortReport.com|
|View AERI Fundamentals - TradeKing||View AERI SEC Filings - Bar Chart|
|View Historical Prices for AERI - The WSJ||View Performance/Total Return for AERI - Morningstar|
|View the Analyst Estimates for AERI - MarketWatch||View the Earnings History for AERI - CNBC|
|View the AERI Earnings - StockMarketWatch||View AERI Buy or Sell Recommendations - MacroAxis|
|View the AERI Bullish Patterns - American Bulls||View AERI Short Pain Metrics - ShortPainBot.com|
|View AERI Stock Mentions - StockTwits||View AERI Stock Mentions - PennyStockTweets|
|View AERI Stock Mentions - Twitter||View AERI Investment Forum News - Investor Hub|
|View AERI Stock Mentions - Yahoo! Message Board||View AERI Stock Mentions - Seeking Alpha|
|View Insider Transactions for AERI - SECform4.com||View Insider Transactions for AERI - Insider Cow|
|View AERI Major Holdings Summary - CNBC||View Insider Disclosure for AERI - OTC Markets|
|View Insider Transactions for AERI - Yahoo! Finance||View Institutional Holdings for AERI - NASDAQ|
|View AERI Stock Insight & Charts - FinViz.com||View AERI Investment Charts - StockCharts.com|
|View AERI Stock Overview & Charts - BarChart||View AERI User Generated Charts - Trading View|
Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa® in the United States and is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105
Posted on Tuesday March 19, 2019
Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion
Posted on Monday March 18, 2019
Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This Phase 2 study (AR1105-CS201) will be conducted at approximately 20 centers in the United States and enroll up to 45 patients. In the initial safety stage, up to 5 patients will be enrolled in a single cohort to receive clinical formulation #1 (CF-1), delivering a 340µg dose of dexamethasone in a single intravitreal injection.
Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
Posted on Wednesday March 13, 2019
Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.